Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INSIDE INDUSTRY
Phosphagenics licenses TPM® platform to Indian pharmaceutical company
Australian drug delivery technology company Phosphagenics Limited has licensed an injectable antibiotic product, harnessing its proprietary TPM® platform technology, to Agila Specialties Private Limited (Agila). Agila is a wholly owned subsidiary of the listed Indian pharmaceutical company, Strides Arcolab (Strides).

Agila has one of the largest steriles capacities in India and amongst the largest lyophilization (freeze drying) capacities in the world with its operations spread over nine world-class manufacturing facilities around the globe. The company is focused on developing and commercializing new products for key therapeutic markets targeting antiinfectives, oncology, central nervous system (CNS), gastro-intestinal (GI), ophthalmics and peptides.

Under the terms of the exclusive global license agreement, Phosphagenics will license the TPM® technology to Agila for its use in an antibiotic injectable product. Agila will be responsible for the development and pay the costs required to register and commercialize the product including all necessary clinical studies.

Phosphagenics will receive an upfront payment as well as undisclosed royalties based on net sales. The size of the antibiotic injectables market is several billion dollars annually.

Company CEO, Dr Esra Ogru, said this agreement demonstrates the versatility of the TPM® platform technology, paving the way for further opportunities in the injectable market.

 “Strides and its subsidiary, Agila, have state-of-the-art manufacturing capabilities and have had tremendous success in bringing new products to market. This will be the first time TPM® will be used in an injectable formulation.”

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.